Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3965 |
Name | Merkel cell carcinoma |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer integumentary system cancer skin cancer skin carcinoma Merkel cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 wild-type | ALRN-6924 | Merkel cell carcinoma | predicted - sensitive | detail... |
RB1 loss | LY3295668 | Merkel cell carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02036476 | Phase II | Cabozantinib | Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma | Terminated | USA | 0 |
NCT02155647 | Phase II | Avelumab | Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200) | Completed | USA | ITA | FRA | ESP | DEU | AUS | 1 |
NCT02267603 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer | Completed | USA | 0 |
NCT02488759 | Phase Ib/II | Nivolumab | A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) | Completed | USA | NLD | GBR | FRA | ESP | DEU | BEL | 4 |
NCT02514824 | Phase Ib/II | Sapanisertib | MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma | Completed | USA | 0 |
NCT02584829 | Phase Ib/II | IFN-B Avelumab | Localized Radiation Therapy or Recombinant Interferon Beta and MSB0010718C With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma | Terminated | USA | 0 |
NCT02643303 | Phase Ib/II | Durvalumab + Poly ICLC Tremelimumab | A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers | Completed | USA | 0 |
NCT02819843 | Phase II | Talimogene laherparepvec | A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors | Completed | USA | 0 |
NCT02831179 | Phase I | Capecitabine + Temozolomide + Veliparib | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | Withdrawn | 0 | |
NCT02936323 | Phase Ib/II | PEN-221 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | Completed | USA | GBR | 0 |
NCT02978625 | Phase II | Nivolumab + Talimogene laherparepvec | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | Active, not recruiting | USA | 0 |
NCT03071406 | Phase II | Ipilimumab + Nivolumab | Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03074513 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | Active, not recruiting | USA | 0 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | POL | NZL | FRA | ESP | AUS | 4 |
NCT03271372 | Phase III | Avelumab | Adjuvant Avelumab in Merkel Cell Cancer (ADAM) | Active, not recruiting | USA | 0 |
NCT03304639 | Phase II | Pembrolizumab | Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer | Active, not recruiting | USA | 0 |
NCT03416335 | Phase Ib/II | DSP-0509 DSP-0509 + Pembrolizumab | A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile | Terminated | USA | 0 |
NCT03435640 | Phase Ib/II | NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 | A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies | Terminated | USA | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03590054 | Phase I | Abexinostat + Pembrolizumab | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | Completed | USA | 0 |
NCT03599713 | Phase II | Retifanlimab | A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma | Completed | USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | AUS | 0 |
NCT03628677 | Phase I | AB154 AB154 + Zimberelimab | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Active, not recruiting | USA | AUS | 0 |
NCT03629756 | Phase I | Etrumadenant + Zimberelimab | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Completed | USA | AUS | 0 |
NCT03712605 | Phase III | Pembrolizumab | Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer | Active, not recruiting | USA | 0 |
NCT03747484 | Phase Ib/II | Avelumab + FH-MCVA2TCR | Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer | Terminated | USA | 0 |
NCT03767348 | Phase Ib/II | Nivolumab + RP1 RP1 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) | Recruiting | USA | GBR | FRA | ESP | DEU | 0 |
NCT03783078 | Phase III | Pembrolizumab | Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) | Completed | USA | SWE | NZL | ITA | FRA | ESP | CAN | AUS | 0 |
NCT03787602 | Phase Ib/II | Avelumab + KRT-232 KRT-232 | Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | Recruiting | USA | NLD | ITA | FRA | ESP | DEU | CAN | BRA | AUS | 1 |
NCT03798639 | Phase I | Ipilimumab + Nivolumab Nivolumab | Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer | Completed | USA | 0 |
NCT03816332 | Phase I | Ipilimumab + Nivolumab + Prednisone + Tacrolimus | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | Active, not recruiting | USA | 0 |
NCT03816345 | Phase I | Nivolumab | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Recruiting | USA | CAN | 0 |
NCT03853317 | Phase II | Avelumab + haNK cells + Nogapendekin alfa inbakicept | Evaluate Efficacy of Avelumab, haNK and N-803 in Subjects With Progressed MCC on or After Checkpoint Inhibitor Therapy. | Terminated | USA | 0 |
NCT03901573 | Phase Ib/II | Atezolizumab + NT-I7 | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | Terminated | USA | 0 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | AUS | 1 |
NCT03988647 | Phase II | Pembrolizumab | Phase II Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma | Terminated | USA | 0 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04160065 | Phase I | IFx-Hu2.0 | Immunotherapy With IFx-Hu2.0 Vaccine for Advanced MCC or cSCC | Completed | USA | 0 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04261855 | Phase Ib/II | Avelumab Avelumab + lutetium Lu 177 dotatate | Targeted Therapy and Avelumab in Merkel Cell Carcinoma (GoTHAM) | Recruiting | AUS | 0 |
NCT04291885 | Phase II | Avelumab | Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma (I-MAT) | Recruiting | NZL | AUS | 0 |
NCT04393753 | Phase II | Avelumab + Domatinostat | Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 (MERKLIN2) | Completed | NLD | ITA | FRA | ESP | DEU | BEL | 0 |
NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04590781 | Phase Ib/II | Pembrolizumab + XmAb18087 XmAb18087 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | Terminated | USA | 0 |
NCT04725331 | Phase Ib/II | BT-001 BT-001 + Pembrolizumab | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | Recruiting | FRA | BEL | 0 |
NCT04787042 | Phase Ib/II | Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Active, not recruiting | USA | 0 |
NCT04792073 | Phase II | Avelumab | Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma | Recruiting | USA | 0 |
NCT04819373 | Phase II | BDB001 | BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors | Completed | USA | 0 |
NCT04869137 | Phase II | Lenvatinib + Pembrolizumab | Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT04874831 | Phase II | Avelumab + Domatinostat | Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1) | Withdrawn | 0 | |
NCT04902040 | Phase Ib/II | Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab + Plinabulin Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | Active, not recruiting | USA | 0 |
NCT04902443 | Phase I | Nivolumab + Pomalidomide | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | Recruiting | USA | 0 |
NCT04916002 | Phase II | Cemiplimab + Vidutolimod | CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer | Terminated | USA | AUS | 0 |
NCT04975152 | Phase I | Cemiplimab | Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT05076760 | Phase I | MEM-288 | Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | 0 |
NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | CAN | AUS | 1 |
NCT05120271 | Phase Ib/II | BOXR1030 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1) | Recruiting | USA | 0 |
NCT05199272 | Phase Ib/II | 23ME-00610 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | Active, not recruiting | USA | CAN | 0 |
NCT05269381 | Phase I | Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) | Recruiting | USA | 0 |
NCT05329792 | Phase II | Daromun | L19IL2/L19TNF in Skin Cancer Patients | Recruiting | ITA | FRA | ESP | 0 |
NCT05422781 | Phase I | ITI-3000 | Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC) | Completed | USA | 0 |
NCT05496036 | Phase II | Pembrolizumab | Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma (MCC) | Recruiting | USA | 0 |
NCT05583708 | Phase II | lutetium Lu 177 dotatate + Pembrolizumab | Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer (iPRRT) | Suspended | USA | 0 |
NCT05594290 | Phase II | Cisplatin + Etoposide + Retifanlimab | Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery (MERCURY) | Recruiting | ITA | 0 |
NCT05859074 | Phase I | MQ710 + Pembrolizumab MQ710 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | Active, not recruiting | USA | 0 |
NCT05896839 | Phase Ib/II | Ipilimumab + Nivolumab + Prednisone + Sirolimus | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | Recruiting | USA | 0 |
NCT05904496 | Phase I | BGB-30813 BGB-30813 + Tislelizumab | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ESP | AUS | 0 |
NCT05947500 | Phase II | M1774 Avelumab + M1774 | Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial | Recruiting | USA | CAN | 0 |
NCT06014086 | Phase I | PH-762 | Intratumoral PH-762 for Cutaneous Carcinoma | Recruiting | USA | 0 |
NCT06021626 | Phase I | CRD3874 | A Study of CRD3874-SI in People With Sarcoma or Merkel Cell Cancer | Recruiting | USA | 0 |
NCT06047379 | Phase Ib/II | NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Recruiting | USA | 0 |
NCT06056895 | Phase II | INCAGN02385 + INCAGN02390 + Retifanlimab | Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma (TRICK-MCC) | Recruiting | USA | 0 |
NCT06086288 | Phase II | Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab | Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naive Advanced meRkel Cell cArcinoma (MCC) (PANDORA) | Not yet recruiting | ITA | 0 |
NCT06151236 | Phase II | Nivolumab + Relatlimab | Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma | Recruiting | AUS | 0 |
NCT06514651 | Phase I | MAQ-001 Ipilimumab + MAQ-001 | MAQ-001 in Patients With Advanced Solid Tumors | Recruiting | FRA | 0 |